High-purity asymmetric 1, 4-dihydropyridine compound and preparation method thereof
By limiting the Z-configuration of benzyl derivatives, high-purity asymmetric 1,4-dihydropyridine compounds were successfully prepared by cyclization and dehydration reaction of (Z)-benzyl derivatives and 3-amino acid ester compounds. This solved the problem of high impurity content in existing technologies and simplified the purification process.
Patent Information
- Application Number
- CN202411242503.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-26
AI Technical Summary
The existing preparation process of asymmetric 1,4-dihydropyridine compounds has the problem that the impurities, dimethyl ester B and diethyl ester C, are relatively large and difficult to remove, which affects the quality of the drug.
High-purity asymmetric 1,4-dihydropyridine compounds were prepared by cyclization and dehydration reaction using (Z)-benzyl derivatives and 3-amino acid esters as raw materials. The configuration of the benzyl derivatives was limited to the Z-type to reduce the impurity content.
Rapid preparation of high-purity asymmetric 1,4-dihydropyridine compounds was achieved, simplifying the purification process and effectively reducing the content of impurities such as dimethyl ester B and diethyl ester C.
Smart Images

Figure CN119019322A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of chemical synthesis, and specifically discloses a high-purity asymmetric 1,4-dihydropyridine compound and a preparation method and application thereof. Background Art
[0002] Hypertension is a progressive cardiovascular disease with complex causes that seriously threatens human health. At present, the clinically used drugs with stable and significant antihypertensive effects are mainly 1,4-dihydropyridine calcium ion antagonists. The selectivity of 1,4-dihydropyridine calcium ion antagonists for the myocardium can increase vasodilation and reduce cardiac load. In order to optimize the efficacy and safety of 1,4-dihydropyridine calcium ion antagonists, scientific researchers have been developing and improving them, and have now developed the third generation of dihydropyridine calcium ion antagonists.
[0003] The most commonly used method for the preparation of 1,4-dihydropyridine compounds is the Hantzsch method, which uses aldehydes, 1,3-dicarbonyl compounds and ammonia as raw materials and reacts in organic solvents such as acetic acid or ethanol. This method is only suitable for the synthesis of 1,4-dihydropyridine compounds with symmetrical structures, such as nifedipine. This method requires less equipment and is simple to operate, but its disadvantages are low product yield and difficulty in product purification. More importantly, most 1,4-dihydropyridine compounds, especially the 1,4-dihydropyridine ring, are asymmetrical, and symmetrical impurities will be produced when using the Hantzsch method.
[0004] It has been reported in the prior art that high-purity nitrendipine can be prepared by optimizing the reaction solvent and controlling the staged temperature increase. However, as the reaction time increases, the content of dimethyl ester B and diethyl ester C impurities in the product is difficult to control, and the dimethyl ester B and diethyl ester C impurities are difficult to completely remove by simple recrystallization purification, which affects the quality of the drug.
[0005] There are also reports of using 2,3-dichlorobenzaldehyde and methyl acetoacetate to prepare an intermediate benzyl derivative through a Knoevenagel condensation reaction, and then cyclizing it with ethyl 3-aminocrotonate through a Michael reaction to obtain felodipine with a total yield of 50%. However, the impurity content of dimethyl ester B and diethyl ester C is relatively high.
[0006] Therefore, developing an asymmetric 1,4-dihydropyridine compound that is easy to operate and has high purity has important practical significance for the development of antihypertensive drugs. Summary of the invention
[0007] In view of the problems that the preparation process of asymmetric 1,4-dihydropyridine compounds in the prior art has defects, resulting in a large content of dimethyl ester B and diethyl ester C impurities in the drug, and the impurities are not easy to remove, which affects the quality of the drug, the present invention provides a high-purity asymmetric 1,4-dihydropyridine compound and a preparation method thereof. The present invention uses (Z)-benzyl derivatives and 3-amino acid ester compounds as main synthetic raw materials, and obtains high-purity asymmetric 1,4-dihydropyridine compounds through cyclization dehydration reaction. The asymmetric 1,4-dihydropyridine compounds obtained by the preparation method provided by the present invention have high purity, and the preparation method is simple, and does not require a complex purification process to remove impurities.
[0008] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions: The first aspect of the present invention provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound, comprising the following steps: using a (Z)-benzyl derivative and a 3-amino acid ester compound as raw materials, and subjecting the raw materials to a cyclization reaction to obtain a high-purity asymmetric 1,4-dihydropyridine compound; Wherein, the structural formula of the (Z)-benzyl derivative is as shown in Formula I;
[0009] Formula I Among them, R 1 C 1 -C 4 The alkyl group , or Any one of R 2 , R 3 -H, -NO 2 , -X or -CN; X is halogen.
[0010] Compared with the prior art, the present invention limits the configuration of the raw material intermediate benzyl derivative for synthesizing asymmetric 1,4-dihydropyridine compounds to Z type. After a large number of experiments, the inventor accidentally discovered that the configuration of the intermediate raw material benzyl derivative used in the synthesis process of asymmetric 1,4-dihydropyridine compounds is related to the impurities of dimethyl ester B and diethyl ester C. Only when the configuration of the benzyl derivative is Z type, the content of impurities dimethyl ester B (impurity II) and diethyl ester C (impurity III) in the asymmetric 1,4-dihydropyridine compounds prepared by cyclization dehydration reaction with 3-amino acid ester compounds is low, and the types and contents of other unknown impurities are small, and high-purity asymmetric 1,4-dihydropyridine compounds can be obtained without complex purification. The use of (Z)-benzyl derivatives can achieve rapid preparation of high-purity asymmetric 1,4-dihydropyridine compounds, and the preparation method is simple, which provides a new idea and basis for the preparation of asymmetric 1,4-dihydropyridine compounds. The technical solution of the present invention effectively solves the problem that the preparation process of asymmetric 1,4-dihydropyridine compounds in the prior art has defects, resulting in a large content of dimethyl ester B and diethyl ester C impurities in the drug, and the impurities are difficult to remove, which affects the quality of the drug.
[0011] Preferably, the preparation method specifically comprises the following steps: dissolving the (Z)-benzyl derivative and the 3-amino acid ester compound in an alcohol solvent, adding a dehydrating agent, and performing a cyclization reaction at 80°C-100°C to obtain a high-purity asymmetric 1,4-dihydropyridine compound.
[0012] Preferably, the structural formula of the 3-amino acid ester compound is as shown in Formula II,
[0013] Formula II Among them, R 4 , R 5 -CH 3 , -CN or Any one of .
[0014] Preferably, the preparation method of the (Z)-benzyl derivative comprises the following steps: the preparation method of the (Z)-benzyl derivative comprises the following steps: using a benzaldehyde derivative and an acetylacetone derivative as raw materials, using a lower alcohol as a solvent, and carrying out a coupling reaction at 10°C-50°C under the action of an organic catalyst to obtain a crude (Z)-benzyl derivative; and recrystallizing and purifying the crude (Z)-benzyl derivative to obtain a (Z)-benzyl derivative.
[0015] Further preferably, the structural formula of the benzaldehyde derivative is as shown in Formula III;
[0016] Formula III Among them, R 2 , R 3 -H, -NO 2 , -X, -CN; X is halogen; and / or Further preferably, the structural formula of the acetylacetone derivative is as shown in Chemical Formula IV,
[0017] Formula IV Among them, R 1 C 1 -C 4 The alkyl group , or Any one of .
[0018] Further preferably, the molar ratio of the benzaldehyde derivative to the acetylacetone derivative is 1:1-1:1.2.
[0019] Further preferably, the added amount of the organic catalyst is 3%-5% of the total mass of the benzaldehyde derivative and the acetylacetone derivative.
[0020] More preferably, the lower alcohol is methanol, ethanol or isopropanol.
[0021] More preferably, the organic catalyst is any one or two of pyridine, piperidine, formic acid, acetic acid or pyridine carboxylate.
[0022] Further preferably, the mass volume ratio of the benzaldehyde derivative to the lower alcohol is 1g:1.5mL-1g:2.5mL.
[0023] Further preferably, the coupling reaction time is 22h-28h.
[0024] Further preferably, the reagents for recrystallization purification are any two of petroleum ether, acetone, n-hexane, n-heptane, ethanol, methanol or water.
[0025] Preferably, the molar ratio of the (Z)-benzyl derivative to the 3-amino acid ester compound is 1:0.9-1:1.1.
[0026] Preferably, the mass volume ratio of the 3-amino acid ester compound to the alcohol solvent is 1g:3mL-1g:6mL.
[0027] Preferably, the dehydrating agent is any one of 3A molecular sieve, 4A molecular sieve or 5A molecular sieve.
[0028] Preferably, the cyclization reaction time is 15h-28h.
[0029] Preferably, the amount of the dehydrating agent added is 30%-50% of the mass of the 3-amino acid ester compound.
[0030] The second aspect of the present invention provides a high-purity asymmetric 1,4-dihydropyridine compound, which is prepared by the preparation method of the high-purity asymmetric 1,4-dihydropyridine compound.
[0031] In summary, the present invention provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compounds. By limiting the configuration of the intermediate benzyl derivative, a high-purity asymmetric 1,4-dihydropyridine compound is successfully prepared. The preparation method provided by the present invention has a simple route, simple operation, and does not require a complicated purification process. The technical solution of the present invention effectively solves the problem that the preparation process of asymmetric 1,4-dihydropyridine compounds in the prior art has defects, resulting in a large content of dimethyl ester B and diethyl ester C impurities in the drug, and the impurities are not easy to remove, affecting the quality of the drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 The hydrogen spectrum of the high-purity asymmetric 1,4-dihydropyridine compound obtained in Example 1; Figure 2 The carbon spectrum of the high-purity asymmetric 1,4-dihydropyridine compound obtained in Example 1; Figure 3 The hydrogen spectrum of the high-purity asymmetric 1,4-dihydropyridine compound obtained in Example 2; Figure 4 The carbon spectrum of the high-purity asymmetric 1,4-dihydropyridine compound obtained in Example 2; Figure 5 This is the hydrogen spectrum of the high-purity asymmetric 1,4-dihydropyridine compound obtained in Example 3; Figure 6 The carbon spectrum of the high-purity asymmetric 1,4-dihydropyridine compound obtained in Example 3; Figure 7 is the two-dimensional H-NMR spectrum of the (Z)-benzyl derivative obtained in Example 1; Figure 8 Be the liquid chromatogram of embodiment 1 obtained felodipine; Fig. 9 The liquid chromatogram of felodipine obtained in Comparative Example 1 is shown. DETAILED DESCRIPTION
[0033] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] Example 1 This embodiment provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (felodipine), which specifically includes the following contents: Step 1: dissolving 100 g of 2,3-dichlorobenzaldehyde, 74 g of methyl acetoacetate, 7 g of picolinic acid and 4.8 g of piperidine in 200 mL of isopropanol, reacting at 25° C. for 24 h. After the reaction is completed, cooling the reaction system to 15° C., standing for crystallization for 2 h, and filtering. The resulting crystals are washed with isopropanol to obtain a crude (Z)-benzyl derivative; the crude (Z)-benzyl derivative is purified by recrystallization using acetone and petroleum ether in a volume ratio of 1:1 to obtain 122 g of a (Z)-benzyl derivative with a yield of 78%; Step 2: uniformly mix the (Z)-benzyl derivative and 57 g of ethyl 3-aminocrotonate, dissolve in 250 mL of isopropanol, add 18 g of 4A molecular sieve, reflux for 15 h, cool to 10° C. after the reaction is complete, let stand, precipitate solid, filter by suction, and rinse with isopropanol to obtain crude felodipine; Step 3: Recrystallize the crude felodipine product with isopropanol to obtain 106 g of felodipine with a yield of 63% and a purity of 99.9%.
[0035] The obtained NMR data of felodipine are: 1 H NMR (500 MHz, CDCl 3 )δ7.30 (dd, J = 7.8, 1.6Hz, 1H), 7.24 (dd, J = 7.9, 1.6 Hz, 1H), 7.06 (t, J = 7.8 Hz, 1H), 5.91 (d, J = 9.1Hz, 1H), 5.46 (s, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.61 (s, 3H), 2.29 (d, J = 5.2Hz, 6H), 1.18 (t, J = 7.1 Hz, 3H). 13 C NMR (126 MHz, CDCl3 )δ168.00, 167.51, 148.20, 144.44, 144.41,144.34, 144.31, 132.79, 130.99, 129.72, 128.27, 127.06, 103.83, 103.81,103.42, 103.40, 59.91, 50.93, 38.63, 19.51, 19.50, 19.45, 19.43, 14.33. Example 2 This embodiment provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (nitrendipine), which specifically includes the following contents: Step 1: dissolving 50 g of m-nitrobenzaldehyde, 48 g of ethyl acetoacetate, 1.4 g of piperidine and 1.0 g of acetic acid in 100 mL of methanol, reacting at 20° C. for 24 h. After the reaction is completed, cooling the reaction system to 10° C., standing for crystallization for 2 h, and filtering. The resulting crystals are washed with methanol to obtain a crude (Z)-benzyl derivative; the crude (Z)-benzyl derivative is purified by recrystallization using acetone and n-hexane in a volume ratio of 1:1 to obtain 70 g of the (Z)-benzyl derivative with a yield of 80%; Step 2: Evenly mix the (Z)-benzyl derivative and 33 g of ethyl 3-aminocrotonate, dissolve in 250 mL of anhydrous ethanol, add 18 g of 5A molecular sieves, and reflux for 26 h. After the reaction is completed, cool to 15° C., let stand, precipitate solid, filter, and rinse with anhydrous ethanol to obtain a crude product of nifedipine; Step 3: Recrystallize the crude nitrendipine using anhydrous ethanol to obtain 74 g of nitrendipine with a yield of 80% and a purity of 99.6%.
[0036] The obtained NMR data of nitrendipine are: 1 H NMR (500 MHz, CDCl 3 )δ8.12 (t, J = 2.0 Hz,1H), 8.00 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 7.64 (dt, J = 7.7, 1.4 Hz, 1H), 7.38(t, J = 7.9 Hz, 1H), 5.89- 5.86 (m, 1H), 5.10 (s, 1H), 4.10 (qq, J = 10.9, 7.1Hz, 2H), 3.64 (s, 3H), 2.37 (d, J= 2.8 Hz, 6H), 1.23 (t, J = 7.1 Hz, 3H). 13 C NMR (126 MHz, CDCl 3 )δ167.62, 167.10, 149.79, 148.31, 145.01,144.76, 134.41, 128.70, 122.97, 121.42, 103.44, 103.14, 60.07, 51.19, 39.85,19.71, 19.65, 14.29. Example 3 This embodiment provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (nimodipine), which specifically includes the following contents: Step 1: dissolving 200 g of m-nitrobenzaldehyde, 210 g of ethyl isopropyl ester, 8 g of picolinic acid and 5.6 g of piperidine in 400 mL of isopropanol, reacting at 30° C. for 24 h. After the reaction is completed, cooling the reaction system to 10° C., standing for crystallization for 2 h, and filtering. The resulting crystals are washed with isopropanol to obtain a crude (Z)-benzyl derivative; the crude (Z)-benzyl derivative is purified by recrystallization using acetone and petroleum ether in a volume ratio of 1:1 to obtain 211 g of the (Z)-benzyl derivative, with a yield of 75%; Step 2: The (Z)-benzyl derivative and 150 g of 3-aminocrotonic acid methoxyethyl ester were mixed evenly, dissolved in 250 mL of anhydrous ethanol, and 18 g of 3A molecular sieves were added. The mixture was refluxed for 26 h. After the reaction was completed, the temperature was lowered to 10° C., a solid was precipitated, and the mixture was allowed to stand for 2 h. The solid was filtered and washed with isopropanol to obtain a crude nimodipine product. Step 3: Recrystallize the crude nimodipine with acetone to obtain 281 g of nimodipine with a yield of 58% and a purity of 99.7%.
[0037] The obtained NMR data of nimodipine are: 1 H NMR (500 MHz, CDCl 3 )δ8.14 (t, J = 2.0 Hz,1H), 8.00 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 7.67 (dt, J = 7.7, 1.4 Hz, 1H), 7.37(t, J = 7.9 Hz, 1H), 5.97 (d, J= 6.8 Hz, 1H), 5.10 (s, 1H), 4.94 (hept, J = 6.2Hz, 1H), 4.18 (qdd, J = 12.1, 5.8, 3.6 Hz, 2H), 3.60-3.49 (m, 2H), 3.35 (s,3H), 2.36 (s, 6H), 1.26 (d, J = 6.3 Hz, 3H), 1.09 (d, J = 6.2 Hz, 3H). 13 C NMR (126 MHz, CDCl 3 )δ167.11, 166.58, 150.04, 148.10, 145.28,144.50, 134.76, 128.60, 123.30, 121.32, 103.85, 103.03, 70.52, 67.38, 63.02,58.88, 40.09, 22.14, 21.82, 19.67, 19.51. Example 4 This embodiment provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (amlodipine), which specifically includes the following contents: Step 1: dissolving 20 g of chlorobenzaldehyde, 18 g of methyl acetoacetate, 0.9 g of picolinic acid and 1 g of piperidine in 40 mL of isopropanol, reacting at 22° C. for 24 h. After the reaction is completed, cooling the reaction system to 15° C., standing for crystallization for 2 h, and filtering. The resulting crystals are washed with isopropanol and dried at 60° C. for 8 h to obtain a crude (Z)-benzyl derivative. The crude (Z)-benzyl derivative is purified by recrystallization using a mixed solvent of petroleum ether and acetone in a volume ratio of 1:1 to obtain 28 g of a (Z)-benzyl derivative with a yield of 75%; Step 2: The (Z)-benzyl derivative and 34 g of ethyl 3-amino-4-(2-phthalimidoethoxy)crotonate are mixed evenly, dissolved in 100 mL of anhydrous ethanol, and 18 g of 4A molecular sieves are added. The mixture is refluxed for 24 h. After the reaction is completed, the temperature is lowered to 12° C., a solid is precipitated, and the mixture is allowed to stand for 2 h. The solid is filtered and washed with isopropanol to obtain a crude amlodipine. Step 3: Recrystallize the crude amlodipine using isopropanol to obtain 27.5 g of amlodipine with a yield of 63% and a purity of 99.8%.
[0038] The NMR data of the obtained ammonia chloride are: 1 H NMR (300 MHz, CDCl3 )δ(ppm):7.40 (br,s,H),7.02-7.37(n,4H),5.39 (s,1H),4.75 (dd,2H),4.02 (q,2H),3.71(m,2H),3.60(s,3H),3.12(m,2H),2.70 (br, 2H), 2.36 (s, 3H) 1.19 (t, 3H). Example 5 This embodiment provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (arandipine), which specifically includes the following contents: Step 1: dissolving 100 g of o-nitrobenzaldehyde, 85 g of methyl acetoacetate, 2.8 g of piperidine and 2.0 g of piperidine in 200 mL of methanol, reacting at 20° C. for 24 h. After the reaction is completed, cooling the reaction system to 10° C., standing for crystallization for 2 h, and filtering. The resulting crystals are washed with methanol to obtain a crude (Z)-benzyl derivative; the crude (Z)-benzyl derivative is purified by recrystallization using acetone and n-heptane in a volume ratio of 1:1 to obtain 75 g of a (Z)-benzyl derivative with a yield of 75%; Step 2: Evenly mix the (Z)-benzyl derivative and 60 g of 3-amino-2-butenoic acid 2,2-ethylenedioxypropyl ester, dissolve in 230 mL of anhydrous ethanol, add 25 g of 4A molecular sieve, reflux for 22 h, then add 20 mL of 10% hydrochloric acid solution and continue to reflux for 2 h. After the reaction is completed, cool to 12 ° C, precipitate solid, stand for 2 h, filter, and rinse with anhydrous ethanol to obtain aranidipine crude product; Step 3: Recrystallize the crude aranidipine with anhydrous ethanol to obtain 65.4 g of aranidipine with a yield of 50% and a purity of 99.0%.
[0039] The obtained NMR data of aranidipine are: 1 H NMR (CDCl 3 )δ:2.03(s,3H),2.29-2.34(s,6H),3.56(s,3H),4.59(d,AB type,2H, J =16.4Hz),5.74(s,1H), 6.61(brs, 1H),7.25~7.6 7(m,4H). 13 CNMR (CDCl 3 )δ:18.7,25.6,34.3,50.7,67.5,101.1,103.3,123.5,126.8,131.1,132.8,142.1,145.1, 147.5,166.1,167.4, 203.3. Example 6 This embodiment provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (clevidipine), which specifically includes the following contents: Step 1: dissolve 25 g of m-nitrobenzaldehyde, 21 g of methyl acetoacetate, 0.7 g of piperidine and 0.5 g of acetic acid in 50 mL of methanol, and react at 25° C. for 24 h. After the reaction is completed, cool the reaction system to 10° C., stand for crystallization for 2 h, and filter. The resulting crystals are washed with isopropanol to obtain a crude (Z)-benzyl derivative. The crude (Z)-benzyl derivative is purified by recrystallization using n-hexane and methanol in a volume ratio of 1:1 to obtain 29 g of the (Z)-benzyl derivative with a yield of 76%. Step 2, the (Z)-benzyl derivative and 19g of ethyl 3-aminocrotonate are mixed evenly, dissolved in 75mL of isopropanol, 7g of 4A molecular sieves are added, and the reaction is refluxed for 24h. After the reaction is completed, part of the solvent is removed, n-heptane is added to the reaction system, stirred and crystallized for 2h, and filtered, the obtained solid is added to methanol, and 20mL of 10% sodium hydroxide solution is added and stirred, and the reaction progress is monitored by TLC. After the reaction is completed, dichloromethane is added to the reaction system for extraction, the organic phase is discarded, the pH of the aqueous phase is adjusted to 2-3, and the solid is precipitated and filtered to obtain a clevidipine precursor; Step 3: Dissolve the clevidipine precursor in 40 mL of N'N-dimethylformamide, add 1.8 g of chloromethyl butyrate and 2.1 g of sodium hydroxide, heat to 80 ° C for reaction for 16 h, monitor the reaction progress by TLC, and after the reaction is completed, pour the reaction system into water, extract with dichloromethane, combine the organic phases, dry the organic phases with sodium sulfate, concentrate under reduced pressure, and recrystallize with a mixed solution of isopropanol and n-hexane to obtain 19.2 g of clevidipine, with a yield of 30% and a purity of 99.5%.
[0040] The obtained NMR data of clevidipine are: 1 H NMR (500 MHz, CDCl 3 )δ7.22-6.96(m,3H), 6.48(s,1H), 5.65(dd,2H, J =5.5Hz, J =16.1Hz), 5.38(s,1H), 3.52(s,1H), 2.21-2.15(m,8H), 1.56-1.48(m,2H), 0.82(t, J = 7.4Hz,3H). 13 C NMR (126 MHz, CDCl 3)δ172.25,167.72,165.82,147.56,147.10,144.22,132.69,130.90,129.64,128.16,126.94,103.61,101.56,78.53, 50.79, 38.30, 35.67,19.44,18.85,17.88,13.35. Comparative Example 1 This comparative example provides a method for preparing a high-purity asymmetric 1,4-dihydropyridine compound (felodipine), which is different from Example 1 in that the (Z)-benzyl derivative is not separated by column chromatography, and other components and amounts remain unchanged, specifically including the following contents: Step 1: Dissolve 100 g of 2,3-dichlorobenzaldehyde, 74 g of methyl acetoacetate, 7 g of picolinic acid and 4.8 g of piperidine in 200 mL of isopropanol, and react at 25°C for 24 h. After the reaction is completed, cool the reaction system to 15°C, stand for crystallization for 2 h, and filter. Wash the resulting crystals with isopropanol to obtain 147 g of (Z)-benzyl derivative with a yield of 82%; Step 2: uniformly mix the (Z)-benzyl derivative and 57 g of ethyl 3-aminocrotonate, dissolve in 250 mL of isopropanol, add 18 g of 4A molecular sieve, reflux for 15 h, cool to 10° C. after the reaction is complete, let stand, precipitate solid, filter by suction, and rinse with isopropanol to obtain crude felodipine; Step 3: Recrystallize the crude felodipine product with isopropanol to obtain 103.8 g of felodipine with a yield of 62% and a purity of 98.9%.
[0041] The obtained NMR data of felodipine are: 1 H NMR (500 MHz, CDCl 3 )δ7.30 (dd, J = 7.8, 1.6Hz, 1H), 7.24 (dd, J = 7.9, 1.6 Hz, 1H), 7.06 (t, J = 7.8 Hz, 1H), 5.91 (d, J = 9.1Hz, 1H), 5.46 (s, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.61 (s, 3H), 2.29 (d, J = 5.2Hz, 6H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl 3 )δ168.00, 167.51, 148.20, 144.44, 144.41,144.34, 144.31, 132.79, 130.99, 129.72, 128.27, 127.06, 103.83, 103.81,103.42, 103.40, 59.91, 50.93, 38.63, 19.51, 19.50, 19.45, 19.43, 14.33. In order to further reflect the technical effect of the present invention, the present invention carried out liquid chromatography test on the felodipine obtained in Example 1 and Comparative Example 1, and the specific test conditions refer to the detection method of felodipine in the Chinese Pharmacopoeia 2020 edition.
[0042] The test results are shown in Table 1-2.
[0043] Table 1 Example 1 obtained felodipine liquid chromatography data analysis table
[0044] Table 2 Comparative Example 1 obtained felodipine liquid chromatography data analysis table
[0045] according to Figure 7 It can be seen that the benzyl derivative used in Example 1 of the present invention is a Z-type configuration. The H on the double bond and the H on the ester group in the felodipine structure have a certain correlation, and the two are located on both sides, which conforms to the Z-type configuration.
[0046] according to Figure 8-9 As can be seen from Table 1-2, compared with Comparative Example 1, the content of impurity II and impurity III is lower in the felodipine obtained in the embodiment of the present invention 1, and the content differs greatly, which can reach tens of times. And, there are more assorted peaks in the felodipine obtained in Comparative Example 1, which illustrates that the impurity of the felodipine obtained in Comparative Example 1 also has more types of unknown impurities except known impurities. This shows that the configuration of benzyl derivatives has a significant impact on the impurity content and the kind of felodipine.
[0047] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a high-purity asymmetric 1,4-dihydropyridine compound, characterized in that: The method comprises the following steps: using (Z)-benzyl derivatives and 3-amino acid ester compounds as raw materials, and performing cyclization reaction to obtain high-purity asymmetric 1,4-dihydropyridine compounds; Wherein, the structural formula of the (Z)-benzyl derivative is shown in Formula I: Formula I Wherein, R1 is a C1-C4 alkyl group, , or Any one of; R2, R3 are any one of -H, -NO2, -X or -CN; X is a halogen.
2. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 1, characterized in that: The preparation method specifically comprises the following steps: dissolving a (Z)-benzyl derivative and a 3-amino acid ester compound in an alcohol solvent, adding a dehydrating agent, and performing a cyclization reaction at 80°C-100°C to obtain a high-purity asymmetric 1,4-dihydropyridine compound.
3. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 1 or 2, characterized in that: The structural formula of the 3-amino acid ester compound is shown in Formula II, Formula II Wherein, R4, R5 are -CH3, -CN or Any one of .
4. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 1 or 2, characterized in that: The preparation method of the (Z)-benzyl derivative comprises the following steps: using benzaldehyde derivative and acetylacetone derivative as raw materials, using lower alcohol as solvent, carrying out coupling reaction at 10°C-50°C under the action of an organic catalyst to obtain a crude (Z)-benzyl derivative; and recrystallizing and purifying the crude (Z)-benzyl derivative to obtain a (Z)-benzyl derivative.
5. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 4, characterized in that: The structural formula of the benzaldehyde derivative is shown in Formula III: Formula III Wherein, R2 and R3 are any one of -H, -NO2, -X, and -CN; X is a halogen; The structural formula of the acetylacetone derivative is shown in Formula IV: Formula IV Wherein, R1 is a C1-C4 alkyl group, , or Any one of .
6. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 4 or 5, characterized in that: The molar ratio of the benzaldehyde derivative to the acetylacetone derivative is 1:1-1:1.2; and / or The added amount of the organic catalyst is 3%-5% of the total mass of the benzaldehyde derivative and the acetylacetone derivative.
7. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 4, characterized in that: The lower alcohol is methanol, ethanol or isopropanol; and / or The organic catalyst is any one or two of pyridine, piperidine, formic acid, acetic acid or pyridine carboxylate; and / or The mass volume ratio of the benzaldehyde derivative to the lower alcohol is 1g:1.5mL-1g:2.5mL; and / or The coupling reaction time is 22h-28h; and / or The reagents for recrystallization purification are any two of petroleum ether, acetone, n-hexane, n-heptane, ethanol, methanol or water.
8. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 2, characterized in that: The molar ratio of the (Z)-benzyl derivative to the 3-amino acid ester compound is 1:0.9-1:1.1; and / or The mass volume ratio of the 3-amino acid ester compound to the alcohol solvent is 1g:3mL-1g:6mL.
9. The method for preparing a high-purity asymmetric 1,4-dihydropyridine compound according to claim 2, characterized in that: The dehydrating agent is any one of 3A molecular sieve, 4A molecular sieve or 5A molecular sieve; and / or The cyclization reaction time is 15h-28h; and / or The amount of the dehydrating agent added is 30%-50% of the mass of the 3-amino acid ester compound.
10. A high-purity asymmetric 1,4-dihydropyridine compound, characterized in that: The compound is prepared by the preparation method of high-purity asymmetric 1,4-dihydropyridine compounds according to any one of claims 1 to 9.
